ZyVersa Therapeutics, Inc. ZVSA
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.50% | -22.10% | -16.69% | -19.58% | -30.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.98% | -25.09% | -21.26% | -24.51% | -33.19% |
| Operating Income | 28.98% | 25.09% | 21.26% | 24.51% | 33.19% |
| Income Before Tax | -186.76% | -174.32% | -21.14% | 63.00% | 91.66% |
| Income Tax Expenses | -12,811.94% | -12,811.94% | -45.75% | 99.49% | 100.08% |
| Earnings from Continuing Operations | -176.91% | -165.07% | -20.47% | 62.02% | 90.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -176.91% | -165.07% | -20.47% | 62.02% | 90.94% |
| EBIT | 28.98% | 25.09% | 21.26% | 24.51% | 33.19% |
| EBITDA | 44.43% | 25.11% | 21.24% | 24.48% | 33.18% |
| EPS Basic | 53.72% | 65.16% | 93.84% | 95.68% | 99.60% |
| Normalized Basic EPS | 85.97% | 85.85% | 88.34% | 90.57% | 95.01% |
| EPS Diluted | 53.72% | 65.16% | 93.84% | 95.68% | 99.60% |
| Normalized Diluted EPS | 85.97% | 85.85% | 88.34% | 90.57% | 95.01% |
| Average Basic Shares Outstanding | 316.01% | 436.36% | 563.20% | 515.62% | 601.41% |
| Average Diluted Shares Outstanding | 316.01% | 436.36% | 563.20% | 515.62% | 601.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |